Tovorafenib (DAY101)

Name: Tovorafenib (DAY101) in RAF-altered pediatric low-grade glioma requiring first-line systemic therapy: Disease description
Published: 2026-09-17T18:16:08-04:00

RAF-altered pediatric low-grade glioma requiring first-line systemic therapy

Also known as TAK-580

Manufacturer: Day One Biopharmaceuticals
Regulatory submission: Not announced
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy

Disease description

162 evidence topics · 57 sources

Definition and etiology10 evidence topics · 9 sources
Epidemiology13 evidence topics · 10 sources
Natural history, survival, and mortality25 evidence topics · 17 sources
Pathophysiology17 evidence topics · 12 sources
Diagnosis13 evidence topics · 13 sources
Clinical presentation - signs and symptoms14 evidence topics · 9 sources
Long-term morbidity18 evidence topics · 13 sources
Burden of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy52 evidence topics · 25 sources